These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 24072590)

  • 1. The putative BH3 mimetic S1 sensitizes leukemia to ABT-737 by increasing reactive oxygen species, inducing endoplasmic reticulum stress, and upregulating the BH3-only protein NOXA.
    Soderquist R; Pletnev AA; Danilov AV; Eastman A
    Apoptosis; 2014 Jan; 19(1):201-9. PubMed ID: 24072590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Multiple BH3 mimetics antagonize antiapoptotic MCL1 protein by inducing the endoplasmic reticulum stress response and up-regulating BH3-only protein NOXA.
    Albershardt TC; Salerni BL; Soderquist RS; Bates DJ; Pletnev AA; Kisselev AF; Eastman A
    J Biol Chem; 2011 Jul; 286(28):24882-95. PubMed ID: 21628457
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Gossypol increases expression of the pro-apoptotic BH3-only protein NOXA through a novel mechanism involving phospholipase A2, cytoplasmic calcium, and endoplasmic reticulum stress.
    Soderquist RS; Danilov AV; Eastman A
    J Biol Chem; 2014 Jun; 289(23):16190-9. PubMed ID: 24778183
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vinblastine rapidly induces NOXA and acutely sensitizes primary chronic lymphocytic leukemia cells to ABT-737.
    Bates DJ; Danilov AV; Lowrey CH; Eastman A
    Mol Cancer Ther; 2013 Aug; 12(8):1504-14. PubMed ID: 23723123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tipping the Noxa/Mcl-1 balance overcomes ABT-737 resistance in chronic lymphocytic leukemia.
    Tromp JM; Geest CR; Breij EC; Elias JA; van Laar J; Luijks DM; Kater AP; Beaumont T; van Oers MH; Eldering E
    Clin Cancer Res; 2012 Jan; 18(2):487-98. PubMed ID: 22128299
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737.
    Del Gaizo Moore V; Brown JR; Certo M; Love TM; Novina CD; Letai A
    J Clin Invest; 2007 Jan; 117(1):112-21. PubMed ID: 17200714
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bcl-2 phosphorylation confers resistance on chronic lymphocytic leukaemia cells to the BH3 mimetics ABT-737, ABT-263 and ABT-199 by impeding direct binding.
    Song T; Chai G; Liu Y; Yu X; Wang Z; Zhang Z
    Br J Pharmacol; 2016 Feb; 173(3):471-83. PubMed ID: 26493374
    [TBL] [Abstract][Full Text] [Related]  

  • 8. γ-Secretase inhibition promotes cell death, Noxa upregulation, and sensitization to BH3 mimetic ABT-737 in human breast cancer cells.
    Séveno C; Loussouarn D; Bréchet S; Campone M; Juin P; Barillé-Nion S
    Breast Cancer Res; 2012 Jun; 14(3):R96. PubMed ID: 22703841
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Platinum compounds sensitize ovarian carcinoma cells to ABT-737 by modulation of the Mcl-1/Noxa axis.
    Simonin K; N'Diaye M; Lheureux S; Loussouarn C; Dutoit S; Briand M; Giffard F; Brotin E; Blanc-Fournier C; Poulain L
    Apoptosis; 2013 Apr; 18(4):492-508. PubMed ID: 23344663
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The BH3 mimetic compound, ABT-737, synergizes with a range of cytotoxic chemotherapy agents in chronic lymphocytic leukemia.
    Mason KD; Khaw SL; Rayeroux KC; Chew E; Lee EF; Fairlie WD; Grigg AP; Seymour JF; Szer J; Huang DC; Roberts AW
    Leukemia; 2009 Nov; 23(11):2034-41. PubMed ID: 19641525
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Concurrent up-regulation of BCL-XL and BCL2A1 induces approximately 1000-fold resistance to ABT-737 in chronic lymphocytic leukemia.
    Vogler M; Butterworth M; Majid A; Walewska RJ; Sun XM; Dyer MJ; Cohen GM
    Blood; 2009 Apr; 113(18):4403-13. PubMed ID: 19008458
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cap-translation inhibitor, 4EGI-1, restores sensitivity to ABT-737 apoptosis through cap-dependent and -independent mechanisms in chronic lymphocytic leukemia.
    Willimott S; Beck D; Ahearne MJ; Adams VC; Wagner SD
    Clin Cancer Res; 2013 Jun; 19(12):3212-23. PubMed ID: 23633452
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bcl-2 is a better ABT-737 target than Bcl-xL or Bcl-w and only Noxa overcomes resistance mediated by Mcl-1, Bfl-1, or Bcl-B.
    Rooswinkel RW; van de Kooij B; Verheij M; Borst J
    Cell Death Dis; 2012 Aug; 3(8):e366. PubMed ID: 22875003
    [TBL] [Abstract][Full Text] [Related]  

  • 14. MEK inhibition enhances ABT-737-induced leukemia cell apoptosis via prevention of ERK-activated MCL-1 induction and modulation of MCL-1/BIM complex.
    Konopleva M; Milella M; Ruvolo P; Watts JC; Ricciardi MR; Korchin B; McQueen T; Bornmann W; Tsao T; Bergamo P; Mak DH; Chen W; McCubrey J; Tafuri A; Andreeff M
    Leukemia; 2012 Apr; 26(4):778-87. PubMed ID: 22064351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modulation of NOXA and MCL-1 as a strategy for sensitizing melanoma cells to the BH3-mimetic ABT-737.
    Lucas KM; Mohana-Kumaran N; Lau D; Zhang XD; Hersey P; Huang DC; Weninger W; Haass NK; Allen JD
    Clin Cancer Res; 2012 Feb; 18(3):783-95. PubMed ID: 22173547
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mcl-1 Phosphorylation defines ABT-737 resistance that can be overcome by increased NOXA expression in leukemic B cells.
    Mazumder S; Choudhary GS; Al-Harbi S; Almasan A
    Cancer Res; 2012 Jun; 72(12):3069-79. PubMed ID: 22525702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. ABT-737 resistance in B-cells isolated from chronic lymphocytic leukemia patients and leukemia cell lines is overcome by the pleiotropic kinase inhibitor quercetin through Mcl-1 down-regulation.
    Russo M; Spagnuolo C; Volpe S; Tedesco I; Bilotto S; Russo GL
    Biochem Pharmacol; 2013 Apr; 85(7):927-36. PubMed ID: 23353698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alterations in the Noxa/Mcl-1 axis determine sensitivity of small cell lung cancer to the BH3 mimetic ABT-737.
    Hauck P; Chao BH; Litz J; Krystal GW
    Mol Cancer Ther; 2009 Apr; 8(4):883-92. PubMed ID: 19372561
    [TBL] [Abstract][Full Text] [Related]  

  • 19. BH3 mimetic ABT-737 and a proteasome inhibitor synergistically kill melanomas through Noxa-dependent apoptosis.
    Miller LA; Goldstein NB; Johannes WU; Walton CH; Fujita M; Norris DA; Shellman YG
    J Invest Dermatol; 2009 Apr; 129(4):964-71. PubMed ID: 18987671
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-administration of ABT-737 and SAHA induces apoptosis, mediated by Noxa upregulation, Bax activation and mitochondrial dysfunction in PTEN-intact malignant human glioma cell lines.
    Foster KA; Jane EP; Premkumar DR; Morales A; Pollack IF
    J Neurooncol; 2014 Dec; 120(3):459-72. PubMed ID: 25139025
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.